Using M5 MicroLC System with the QTRAP® 6500+ System
Khatereh Motamedchaboki and Baljit K. Ubhi
SCIEX, USA
Many metabolites are extremely polar and difficult to analyze with reverse phase (RP) chromatography alone, and is therefore metabolomic studies are often done both reversed phase and normal phase, in negative and positive ion modes requiring as many as four injections. Here, a single 30 min LC-MRM targeted screening method using HILIC chromatography including over 300 polar metabolites across multiple biochemical pathways was developed on the QTRAP 6500+ system. The method was run using both analytical flow and microflow chromatography to compare sensitivity and detection rates, and microflow provided up to 50% increase in detection of polar metabolites.
Metabolomics analysis in urine or plasma allows discovery of novel therapeutics, screening for drug toxicity and efficacy, and monitoring diet and environmental exposure effects on health. LC-MS/MS analysis has become an essential tool for identification and quantitation of metabolites in complex sample matrices due to its inherent sensitivity gains.1,2,3 Many of the metabolites of interest in the study of metabolomics are extremely polar and therefore often unable to be analyzed through traditional coupling of reversed phase (RP) chromatography and mass spectrometry. Also to detect and quantify key metabolites from pathways of biochemical importance samples must be run on both reversed phase and normal phase, in negative and positive ion modes requiring a total of four injections.
Here, a robust and sensitive workflow using microflow LC coupled to a QTRAP 6500+ System for screening of over 300 polar metabolites (Figure 1) in biological samples is described. Using HILIC chromatography and polarity switching, a single injection workflow was developed and both analytical and microflow regimes were compared to investigate the impact of flow rate on metabolite detection.
Sample preparation: Urine was diluted in water (1:4) and 100 μL of diluted urine or 100 μL of control plasma for amino acid analysis (SCIEX) was transferred to a clear maximum recovery 1.5 mL microtube (Axygen). 20 μL of internal standards were spiked in the tube and 800 μL of cooled acetonitrile:acetone:methanol (8:1:1) was added to extract metabolites and precipitate the proteins. Samples were vortexed and incubated at 4 ºC for 30 min then centrifuged for 10 min. An 800 μL aliquot of the supernatant was transferred to a new 2 mL microtube then dried to a pellet.
The fresh pellet was dissolved in 100 μL of HILIC sample resuspension buffer (95% acetonitrile and 5 % mobile phase A), mixed well by vortexing and centrifuged for 10 min. Injection volume was 2 µL with 5 replicate injections. Samples were also diluted further (1:3) to check the method sensitivity.
Madin-Darby Canine Kidney Epithelial Cells (MDCK Line) were extracted in 70% methanol and dried to a pellet, dissolved in HILIC sample resuspension buffer. The solubility of the polar metabolites was evaluated in the HILIC sample resuspension buffer containing 100%, 85% and 75% mobile phase B (Figure 3).
Analytical flow chromatography: A SCIEX ExionLC™ AD HPLC System was used for the analytical flow part of the analysis. The columns used were a Luna 3 µm NH2 100 Å, 150 x 4.6 mm column (Phenomenex). Flow rate of 350 µL/min, wash solvent for the autosampler was 20/20/60 methanol/acetonitrile/isopropanol. Injection volume was 2 µL, and the column was kept at 40°C. The gradient used is described in Table 1.
Microflow flow chromatography: A SCIEX M5 MicroLC System was used in direct injection mode. A Luna 3 µm NH2 100 Å, 150 x 0.3 mm analytical column (Phenomenex) was used with a micro filter 1 µm SS (Upchurch Scientific) before the column to prolong column life time. Flow rate of 10 µL/min was used. The column temperature was set to 40°C. Injection volume was 2 µL, and the autosampler needle and valve wash consisted of 1 cycle using mobile phase A, followed by two cycles using mobile phase B. The gradient used is described in Table 1.
Mass spectrometry: A SCIEX QTRAP 6500+ System with IonDrive Turbo V Source was used. For the microflow LC experiments, the standard 100 µm electrode was replaced with a 25 µm ID electrode (SCIEX). MS source parameters were optimized for analytical and microflow (Table 2). A total of 187 positive ion mode MRM’s and 176 negative ion mode MRM’s for a total 312 unique polar metabolites were combined into a single +/- switching experiment (363 total MRM transitions) with 3 msec dwell time and 50 msec settling time for polarity switching to monitor these endogenous metabolites across different metabolic pathways.
Data processing: MultiQuant™ Software 3.0.2 was used for data analysis with MQ4 peak integration algorithm, gaussian smooth width of 1.0 points, RT half window of 30 sec and min peak width of 8 points. Integrated peaks with minimum signal to S/N of 10 or more in all replicates were selected and manually validated. Samples for both microflow and traditional flow LC-MS/MS analysis were prepared on the same day to exclude variations in response due to sample preparation. Five replicate LC-MS/MS injections were acquired for both analytical flow and microflow LC analysis.
When using the typical aqueous sample solvent for sample reconstitution, it is difficult to inject larger volumes of samples without sacrificing HILIC chromatographic resolution. Here, by simply reconstituting the sample in organic solvent (100% mobile phase B), injection volumes up to 5 µL were possible on the microflow LC column, while maintaining good peak shape.
MultiQuant software integrated peaks for the urine metabolites were compared where the metabolite pellet was reconstituted either in 75, 85 or 100% mobile phase B. The metabolite pellet dissolved in 100% B (the LC method starting buffer) shows improved sensitivity and S/N ratio for targeted polar metabolites (Figure 2).
The S/N ratio for all detected metabolites using this MRM method with both analytical flow LC and microflow LC were compared. For each detected metabolite in urine, the lowest observed S/N (calculated by MultiQuant Software) was plotted versus the number of replicates that the metabolite was detected in (Figure 3). 197 metabolites that were detected with S/N ≥20 are seen in all 5 replicates, and therefore considered to be detectable with high confidence without requiring further manual validation. 22 of the metabolites detected with a lowest S/N of 10-20, were manually validated. All of these were detected in all 5 replicates with a manually determined S/N of at least 5.
The microflow HILIC LC-MRM method improved the S/N ratio by up to 60X with an average improvement of 10X (Figure 4). This improved sensitivity resulted in higher number of metabolite detection with a 50% improvement in MDCK cell line, 35% in urine and 11% in plasma when compared to analytical HILIC LC-MRM (Table 3).
Using this 30 min microflow HILIC LC-MRM workflow, a large # of metabolites were detected at a S/N ratio ≥10 in the 3 samples tested (Table 4). Figures 5 and 6 clearly show improved S/N ratio for select metabolites when using the microflow LC-MRM vs. analytical LC-MRM. The improved S/N ratio provided by microflow HILIC method provides solid detection of large numbers of metabolites and up to 50% improvement in detection when compared to data obtained with the analytical flow HILIC method.
Often metabolite extracts must be run on reversed phase and normal phase and both in negative and positive ion modes for detection of such large number of polar metabolites. Here, a single injection workflow with polarity switching detects high numbers of metabolites in biological samples.
This 30 min method is a single LC-MRM targeted screening method allowing detection of over 300 polar metabolites across multiple biochemical pathways involved in cancer, cardiovascular, neurodegenerative, diabetes and obesity.